Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
METIS Innovative is a physician-founded investment firm established in 2017, dedicated to improving the lives of individuals suffering from neurologic illnesses through advancements in neurotechnology. The firm was co-founded by two prominent neurosurgeons, Brian A. Sidman and Dimitri Sigounas, MD, alongside Christopher Kellner, a veteran in capital accrual. This unique founding team combines deep clinical expertise with financial acumen to identify and invest in early-stage medical devices and technologies within the neurosciences sector.
As of now, METIS Innovative manages a portfolio of 8 companies, focusing primarily on the biotech and healthcare sectors. The firm operates with a clear mission to enhance patient outcomes through innovative solutions in neurotechnology. Their approach integrates clinical insights from practicing neurosurgeons with rigorous financial analysis, allowing them to pinpoint high-potential investment opportunities. METIS Innovative is headquartered in the United States, although specific office locations are not disclosed.
METIS Innovative invests in early-stage companies that are developing medical devices and technologies aimed at treating neurologic conditions. Their investment strategy is characterized by a combination of clinical insights from practicing neurosurgeons and comprehensive financial analysis. This dual approach enables them to identify high-potential opportunities in the neurotechnology space, particularly in the pre-seed, seed, seed-plus, and Series A stages.
The firm specifically targets sectors within biotech and healthcare, focusing on innovations that address neurologic illnesses. METIS seeks to partner with founders who demonstrate a strong understanding of their market and possess a clear vision for their technology's impact. They prefer to engage in deal structures that allow for collaborative growth and often consider co-investment opportunities to enhance their portfolio's value.
METIS Innovative's portfolio includes 8 notable companies, each contributing to advancements in neurotechnology:
Brian A. Sidman: Co-Founder of METIS Innovative, Brian brings extensive experience in neurosurgery and investment. His clinical background informs the firm's investment strategy, focusing on high-potential neurotechnology.
Dimitri Sigounas, MD: Co-Founder and practicing neurosurgeon, Dimitri leverages his medical expertise to identify promising investment opportunities in the healthcare sector.
Christopher Kellner: Co-Founder with a strong background in capital accrual, Christopher plays a crucial role in the financial analysis and strategic direction of the firm.
Submit your pitch through their website contact form for consideration.
What are METIS Innovative's investment criteria?
METIS Innovative focuses on early-stage companies developing medical devices and technologies for neurologic conditions. They look for innovative solutions that can significantly improve patient outcomes.
How can I apply or pitch to METIS Innovative?
Founders interested in pitching to METIS Innovative should prepare a detailed presentation that outlines their technology, market potential, and team expertise. Specific application forms or portals are not mentioned, but inquiries can be made through their website.
What makes METIS Innovative different from other venture capital firms?
The unique combination of clinical insights from practicing neurosurgeons and financial analysis sets METIS Innovative apart. This approach allows them to identify high-potential opportunities in neurotechnology that may be overlooked by traditional investors.
What is the geographic scope of METIS Innovative's investments?
While specific geographic preferences are not disclosed, METIS Innovative operates primarily within the United States, focusing on companies that align with their investment thesis in neurotechnology.
What is the typical check size for investments?
METIS Innovative invests in early-stage rounds, including pre-seed, seed, seed-plus, and Series A stages. Specific check sizes are not provided, but they typically align with the funding needs of early-stage companies.
What kind of post-investment involvement can founders expect?
Founders can expect active engagement from METIS Innovative, leveraging the clinical and financial expertise of their team to support growth and development post-investment.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.